Daratumumab (JNJ-54767414)
Showing 576 - 600 of 632
Histamine Induced Itch Trial in Harrow (A:JNJ-39758979/Placebo #1, C:Cetirizine/JNJ-39758979 Matching Placebo, B: JNJ-39758979
Completed
- Histamine Induced Itch
- A:JNJ-39758979/Placebo #1
- +2 more
-
Harrow, United Kingdom(unnamed)
Sep 3, 2013
Seasonal Allergic Rhinitis Trial in Mississauga (JNJ38224342, JNJ38224342/)
Completed
- Seasonal Allergic Rhinitis
- JNJ38224342
- JNJ38224342/placebo
-
Mississauga, Ontario, Canada(unnamed)
Sep 3, 2013
Multiple Myeloma Trial in Japan (JNJ-26866138 0.7 mg/m2, JNJ-26866138 1.0 mg/m2, JNJ-26866138 1.3 mg/m2)
Completed
- Multiple Myeloma
- JNJ-26866138 0.7 mg/m2
- +4 more
-
Fukuoka, Japan
- +27 more
Oct 31, 2013
Healthy Trial in Antwerpen (JNJ-40411813 50 mg, JNJ-40411813 100 mg, Placebo)
Completed
- Healthy
- JNJ-40411813 50 mg
- +2 more
-
Antwerpen, Belgium(unnamed)
Aug 27, 2013
Diabetes, Type II, Diabetes, Non Insulin Dependent Trial in Worldwide (Canagliflozin (JNJ-28431754), Sitagliptin, Placebo)
Completed
- Diabetes Mellitus, Type II
- Diabetes Mellitus, Non Insulin Dependent
- Canagliflozin (JNJ-28431754)
- +2 more
-
Birmingham, Alabama
- +84 more
Jul 15, 2013
Healthy Trial in Neptune (JNJ-38518168 3 mg, JNJ-38518168 30 mg, JNJ-38518168 10 mg)
Completed
- Healthy
- JNJ-38518168 3 mg
- +3 more
-
Neptune, New Jersey(unnamed)
Jul 15, 2013
Healthy Participants Trial in Antwerp (JNJ-47910382 (suspension), JNJ-47910382 (tablet))
Completed
- Healthy Participants
- JNJ-47910382 (suspension)
- JNJ-47910382 (tablet)
-
Antwerp, Belgium(unnamed)
Jul 22, 2013
Healthy Trial in Cypress (JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg)
Completed
- Healthy
- JNJ-39439335 10 mg
- +3 more
-
Cypress, California(unnamed)
Jun 24, 2013
Obesity Trial in Puerto Rico, United States (Canagliflozin (JNJ-28431754), Placebo)
Completed
- Obesity
- Canagliflozin (JNJ-28431754)
- Placebo
-
Hot Springs, Arkansas
- +35 more
Apr 1, 2013
Diabetes, Type 2 Trial in Chula Vista, San Antonio (Placebo, JNJ 28431754 300 mg/, JNJ 28431754 100 mg/)
Completed
- Diabetes Mellitus, Type 2
- Placebo
- +2 more
-
Chula Vista, California
- +1 more
May 27, 2013
Heart Failure Trial in Worldwide (JNJ-39588146 5 ng/kg/min, JNJ-39588146 15 ng/kg/min, JNJ-39588146 30 ng/kg/min)
Completed
- Heart Failure
- JNJ-39588146 5 ng/kg/min
- +4 more
-
Aalst, Belgium
- +8 more
Jul 8, 2013
Rheumatoid Arthritis Trial in United States (JNJ-38518168 / MTX)
Completed
- Rheumatoid Arthritis
- JNJ-38518168 / MTX
-
Anniston, Alabama
- +3 more
May 3, 2013
Renal Insufficiency, Healthy Trial in Orlando, Minneapolis, Knoxville (Canagliflozin (JNJ-28431754))
Completed
- Renal Insufficiency
- Healthy
- Canagliflozin (JNJ-28431754)
-
Orlando, Florida
- +2 more
May 27, 2013
Rheumatoid Arthritis Trial in Worldwide (JNJ 38518168, Placebo)
Terminated
- Rheumatoid Arthritis
- JNJ 38518168
- Placebo
-
Liege, Belgium
- +33 more
Apr 22, 2013
Acne Vulgaris Trial in Fukukoka, Hakata (JNJ 10229570-AAA 1.2%, JNJ 10229570-AAA 3.6%, Color-matched vehicle containing 0 mg of
Completed
- Acne Vulgaris
- JNJ 10229570-AAA 1.2%
- +2 more
-
Fukukoka, Japan
- +1 more
Feb 18, 2013
Rheumatoid Arthritis Trial in Germany, United States (JNJ-39758979 / MTX)
Completed
- Rheumatoid Arthritis
- JNJ-39758979 / MTX
-
Daytona Beach, Florida
- +4 more
Mar 12, 2013
Healthy Male Volunteer Trial in Cypress (JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg))
Completed
- Healthy Male Volunteer
- JNJ-38518168 (30 mg)
- +4 more
-
Cypress, California(unnamed)
Mar 1, 2013